

重篤な有害事象、有害事象による死亡例、副作用による死亡例

1839IL/0709

CATEGORIES OF ADVERSE EVENTS (BY PATIENTS) BY ETHNIC GROUP
POPULATION: EVALUABLE-FOR-SAFETY

	GEFITINIB				PLACEBO				ALL			
	ORIENTAL		NON-ORIENTAL		ORIENTAL		NON-ORIENTAL		ORIENTAL		NON-ORIENTAL	
	N	%	N	%	N	%	N	%	N	%	N	%
	N=235		N=891		N=107		N=455		N=342		N=1346	
Patient had an AE	227	96.6	700	78.6	92	86.0	305	67.0	319	93.3	1005	74.7
Treatment-Related AE	178	75.7	480	53.9	41	38.3	120	26.4	219	64.0	600	44.6
Serious AE	55	23.4	161	18.1	24	22.4	74	16.3	79	23.1	235	17.5
Serious Treatment-Related AE	7	3.0	20	2.2	1	0.9	7	1.5	8	2.3	27	2.0
Non-Fatal Serious AE	52	22.1	128	14.4	19	17.8	64	14.1	71	20.8	192	14.3
Discontinuation Due To AE	17	7.2	44	4.9	2	1.9	11	2.4	19	5.6	55	4.1
Discontinuation Due To Treatment-Related AE	9	3.8	22	2.5	0	0	3	0.7	9	2.6	25	1.9
Discontinuation Due To Serious AE	11	4.7	22	2.5	2	1.9	8	1.8	13	3.8	30	2.2
Discontinuation Due To Serious Treatment-Related AE	5	2.1	5	0.6	0	0	3	0.7	5	1.5	8	0.6
Death Due To AE	11	4.7	44	4.9	6	5.6	16	3.5	17	5.0	60	4.5
Death Due To Treatment-Related AE	2	0.9	3	0.3	0	0	1	0.2	2	0.6	4	0.3
CTC Grade 3 or 4 AE	101	43.0	240	26.9	38	35.5	113	24.8	139	40.6	353	26.2
CTC Grade 3 or 4 Treatment-Related AE	27	11.5	63	7.1	1	0.9	15	3.3	28	8.2	78	5.8
Interstitial Lung Disorder Type Events	7	3.0	5	0.6	4	3.7	1	0.2	11	3.2	6	0.4

ADVERSE EVENTS OCCURRING DURING FOLLOW-UP (I.E. OCCURRING WITHIN 30 DAYS AFTER DISCONTINUATION OF INVESTIGATIONAL PRODUCT) ARE INCLUDED

1839IL/0709

NUMBER OF PATIENTS WITH SERIOUS ADVERSE EVENTS

POPULATION: EVALUABLE-FOR- SAFETY

SYSTEM ORGAN CLASS	PREFERRED TERM	TREATMENT RECEIVED																					
		GEFITINIB					PLACEBO																
		ORIENTAL		NON-ORIENTAL		TOTAL		ORIENTAL		NON-ORIENTAL		TOTAL											
		N=235					N=891					N=107					N=455						
		N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
BLOOD AND LYMPHATIC SYSTEM DISORDERS	TOTAL	3	1.3	8	0.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7
	ANAEMIA	2	0.9	8	0.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.4
	FEBRILE NEUTROPENIA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2
	NEUTROPENIA	1	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	TOTAL	6	2.6	10	1.1	1	0.1	1	0.1	1	0.9	11	2.4	0	0	0	0	0	0	0	0	0	0
CARDIAC DISORDERS	TOTAL	1	0.4	1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	ACUTE MYOCARDIAL INFARCTION	0	0	1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	ANGINA PECTORIS	0	0	1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2
	ARRHYTHMIA	0	0	1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	ARRHYTHMIA SUPRAVENTRICULAR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2
	ATRIAL FIBRILLATION	1	0.4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2
	BRADYCARDIA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	CARDIAC FAILURE	1	0.4	1	0.1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2

(Continued)

MEDDRA VERSION 7.1
 A PATIENT CAN ONLY BE COUNTED ONCE WITHIN ANY SPECIFIC PREFERRED TERM
 ALL PERCENTAGES SHOWN ARE OF TOTAL PATIENTS IN TREATMENT GROUP AND DO NOT NECESSARILY ADD UP TO 100%
 WITHIN SYSTEM ORGAN CLASS
 ADVERSE EVENTS OCCURRING PRE-TRIAL ARE NOT INCLUDED
 ADVERSE EVENTS OCCURRING DURING FOLLOW-UP (I.E. OCCURRING WITHIN 30 DAYS AFTER DISCONTINUATION OF
 INVESTIGATIONAL PRODUCT) ARE INCLUDED

1839IL/0709

NUMBER OF PATIENTS WITH SERIOUS ADVERSE EVENTS

POPULATION: EVALUABLE-FOR-SAFETY

SYSTEM ORGAN CLASS	PREFERRED TERM	TREATMENT RECEIVED											
		GEFITINIB					PLACEBO						
		ORIENTAL		NON-ORIENTAL		ORIENTAL		NON-ORIENTAL		ORIENTAL		NON-ORIENTAL	
		N=235		N=891		N=107		N=455					
		N	%	N	%	N	%	N	%	N	%	N	%
CARDIAC DISORDERS	CARDIAC FAILURE CONGESTIVE	0	0	1	0.1	0	0	0	0	0	0	0	0
	CARDIAC TAMPONADE	1	0.4	0	0	0	0	0	0	0	0	0	0
	CARDIOPULMONARY FAILURE	0	0	1	0.1	0	0	0	0	1	0.2	1	0.2
	COR. PULMONALE	0	0	0	0	0	0	0	0	0	0	1	0.2
	CORONARY ARTERY DISEASE	1	0.4	0	0	0	0	0	0	0	0	0	0
	MYOCARDIAL INFARCTION	1	0.4	3	0.3	1	0.9	2	0.4	0	0	0	0
	MYOCARDIAL ISCHAEMIA	0	0	0	0	0	0	0	0	0	0	1	0.2
	PERICARDIAL EFFUSION	1	0.4	0	0	0	0	0	0	0	0	2	0.4
	SILENT MYOCARDIAL INFARCTION	0	0	1	0.1	0	0	0	0	0	0	0	0
	SUPRAVENTRICULAR TACHYCARDIA	0	0	0	0	0	0	0	0	0	0	1	0.2
	TOTAL	0	0	0	0	0	0	0	0	0	0	1	0.2
CONGENITAL, FAMILIAL AND GENETIC DISORDERS	TRACHEO-OESOPHAGEAL FISTULA	0	0	0	0	0	0	0	0	0	0	1	0.2

(Continued)

MEDDRA VERSION 7.1
 A PATIENT CAN ONLY BE COUNTED ONCE WITHIN ANY SPECIFIC PREFERRED TERM WITHIN SYSTEM ORGAN CLASS
 ALL PERCENTAGES SHOWN ARE OF TOTAL PATIENTS IN TREATMENT GROUP AND DO NOT NECESSARILY ADD UP TO 100%
 ADVERSE EVENTS OCCURRING PRE-TRIAL ARE NOT INCLUDED
 ADVERSE EVENTS OCCURRING DURING FOLLOW-UP (I.E. OCCURRING WITHIN 30 DAYS AFTER DISCONTINUATION OF INVESTIGATIONAL PRODUCT) ARE INCLUDED

1839IL/0709

NUMBER OF PATIENTS WITH SERIOUS ADVERSE EVENTS

POPULATION: EVALUABLE-FOR- SAFETY

SYSTEM ORGAN CLASS	PREFERRED TERM	TREATMENT RECEIVED									
		GEFITINIB				PLACEBO					
		ORIENTAL	NON-ORIENTAL	ORIENTAL	NON-ORIENTAL	ORIENTAL	NON-ORIENTAL	ORIENTAL	NON-ORIENTAL		
		N=235				N=455					
		N	%	N	%	N	%	N	%	N	%
EAR AND LABYRINTH DISORDERS		0	0	1	0.1	0	0	0	0	0	0
TOTAL		0	0	1	0.1	0	0	0	0	0	0
EYE DISORDERS		0	0	1	0.1	0	0	0	0	0	0
TOTAL		0	0	1	0.1	0	0	0	0	0	0
CATARACT		0	0	0	0	0	0	0	0	1	0.2
RETINITIS		0	0	0	0	0	0	0	0	1	0.2
TOTAL		0	0	0	0	0	0	0	0	1	0.2
GASTROINTESTINAL DISORDERS		4	1.7	28	3.1	2	1.9	8	1.8		
ABDOMINAL PAIN		0	0	2	0.2	0	0	0	0	1	0.2
ASCITES		0	0	0	0	0	0	0	0	1	0.2
CONSTIPATION		0	0	5	0.6	0	0	0	0	0	0
DIARRHOEA		0	0	9	1.0	0	0	2	0.4		
DYSPHAGIA		0	0	2	0.2	0	0	0	0	0	0
ENTEROVESICAL FISTULA		0	0	0	0	0	0	0	0	1	0.2

(Continued)

MEDDRA VERSION 7.1
 A PATIENT CAN ONLY BE COUNTED ONCE WITHIN ANY SPECIFIC PREFERRED TERM
 ALL PERCENTAGES SHOWN ARE OF TOTAL PATIENTS IN TREATMENT GROUP AND DO NOT NECESSARILY ADD UP TO 100%
 WITHIN SYSTEM ORGAN CLASS
 ADVERSE EVENTS OCCURRING PRE-TRIAL ARE NOT INCLUDED
 ADVERSE EVENTS OCCURRING DURING FOLLOW-UP (I.E. OCCURRING WITHIN 30 DAYS AFTER DISCONTINUATION OF
 INVESTIGATIONAL PRODUCT) ARE INCLUDED

1639IL/0709

NUMBER OF PATIENTS WITH SERIOUS ADVERSE EVENTS

POPULATION: EVALUABLE FOR SAFETY

SYSTEM ORGAN CLASS	PREFERRED TERM	TREATMENT RECEIVED									
		GEFITINIB					PLACEBO				
		ORIENTAL		NON-ORIENTAL		%	ORIENTAL		NON-ORIENTAL		%
		N=235		N=891			N=107		N=455		
		N	%	N	%	%	N	%	N	%	%
GASTROINTESTINAL DISORDERS	GASTRIC ULCER	0	0	0	0	0	1	0.9	0	0	0
	GASTRITIS	1	0.4	1	0.1	0	0	0	0	0	0
	GASTROINTESTINAL HAEMORRHAGE	0	0	0	0	0	0	0	2	0.4	0
	GASTROINTESTINAL OBSTRUCTION	0	0	0	0	0	1	0.9	0	0	0
	INTESTINAL INFARCTION	0	0	0	0	0	0	0	1	0.2	0
	NAUSEA	0	0	6	0.7	0	0	0	2	0.4	0
	PANCREATITIS	0	0	1	0.1	0	0	0	0	0	0
	PANCREATITIS ACUTE	1	0.4	0	0	0	0	0	0	0	0
	SMALL INTESTINAL OBSTRUCTION	0	0	1	0.1	0	0	0	0	0	0
	SWOLLEN TONGUE	0	0	1	0.1	0	0	0	0	0	0
	UPPER GASTROINTESTINAL HAEMORRHAGE	1	0.4	0	0	0	0	0	0	0	0

(Continued)

MEDDRA VERSION 7.1
 A PATIENT CAN ONLY BE COUNTED ONCE WITHIN ANY SPECIFIC PREFERRED TERM
 ALL PERCENTAGES SHOWN ARE OF TOTAL PATIENTS IN TREATMENT GROUP AND DO NOT NECESSARILY ADD UP TO 100%
 WITHIN SYSTEM ORGAN CLASS
 ADVERSE EVENTS OCCURRING PRE-TRIAL ARE NOT INCLUDED
 ADVERSE EVENTS OCCURRING DURING FOLLOW-UP (I.E. OCCURRING WITHIN 30 DAYS AFTER DISCONTINUATION OF
 INVESTIGATIONAL PRODUCT) ARE INCLUDED

1839IL/0709

NUMBER OF PATIENTS WITH SERIOUS ADVERSE EVENTS

POPULATION: EVALUABLE-FOR- SAFETY

SYSTEM ORGAN CLASS	PREFERRED TERM	TREATMENT RECEIVED											
		GEEITINIB				PLACEBO							
		ORIENTAL	NON-ORIENTAL	ORIENTAL	NON-ORIENTAL	ORIENTAL	NON-ORIENTAL	ORIENTAL	NON-ORIENTAL				
		N=891				N=107				N=455			
		N	%	N	%	N	%	N	%	N	%	N	%
GASTROINTESTINAL DISORDERS	VOMITING	1	0.4	5	0.6	0	0	0	0	1	0.2	0	0
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS	TOTAL	5	2.1	16	1.8	0	0	0	0	8	1.8	0	0
	ASTHENIA	1	0.4	4	0.4	0	0	0	0	0	0	0	0
	DEATH	0	0	2	0.2	0	0	0	0	3	0.7	0	0
	FATIGUE	0	0	3	0.3	0	0	0	0	2	0.4	0	0
	GENERAL PHYSICAL HEALTH DETERIORATION	0	0	1	0.1	0	0	0	0	0	0	0	0
	GENERALISED OEDEMA	1	0.4	1	0.1	0	0	0	0	0	0	0	0
	MALaise	0	0	1	0.1	0	0	0	0	0	0	0	0
	NON-CARDIAC CHEST PAIN	0	0	0	0	0	0	0	0	1	0.2	0	0
	OEDEMA PERIPHERAL	0	0	0	0	0	0	0	0	1	0.2	0	0
	PYREXIA	3	1.3	4	0.4	0	0	0	0	1	0.2	0	0

(Continued)

MEDDRA VERSION 7.1
 A PATIENT CAN ONLY BE COUNTED ONCE WITHIN ANY SPECIFIC PREFERRED TERM
 ALL PERCENTAGES SHOWN ARE OF TOTAL PATIENTS IN TREATMENT GROUP AND DO NOT NECESSARILY ADD UP TO 100%
 WITHIN SYSTEM ORGAN CLASS

ADVERSE EVENTS OCCURRING PRE-TRIAL ARE NOT INCLUDED
 ADVERSE EVENTS OCCURRING DURING FOLLOW-UP (I.E. OCCURRING WITHIN 30 DAYS AFTER DISCONTINUATION OF INVESTIGATIONAL PRODUCT) ARE INCLUDED

1839LL/0709

NUMBER OF PATIENTS WITH SERIOUS ADVERSE EVENTS

POPULATION: EVALUABLE-FOR- SAFETY

SYSTEM ORGAN CLASS	PREFERRED TERM	TREATMENT RECEIVED									
		GEFITINIB			PLACEBO						
		ORIENTAL N=235	NON-ORIENTAL N=891	NON-ORIENTAL N=107	ORIENTAL N=455	ORIENTAL N=107	NON-ORIENTAL N=455				
		N	%	N	%	N	%	N	%	N	%
HEPATOBIILIARY DISORDERS	TOTAL	3	1.3	2	0.2	0	0	1	0.2	0	0
	CHOLECYSTITIS ACUTE	1	0.4	1	0.1	0	0	0	0	0	0
	CHOLELITHIASIS	0	0	1	0.1	0	0	0	0	0	0
	HEPATIC CIRRHOSIS	1	0.4	0	0	0	0	0	0	0	0
	HEPATITIS	1	0.4	0	0	0	0	0	0	0	0
IMMUNE SYSTEM DISORDERS	HEPATOTOXICITY	0	0	0	0	0	0	1	0.2	0	0
	TOTAL	1	0.4	0	0	0	0	0	0	0	0
	ALLERGY TO ANIMAL	1	0.4	0	0	0	0	0	0	0	0
INFECTIONS AND INFESTATIONS	TOTAL	23	9.8	41	4.6	15	14.0	21	4.6	0	0
	BRONCHITIS	0	0	1	0.1	0	0	0	0	0	0
	BRONCHITIS ACUTE	0	0	1	0.1	0	0	0	0	0	0
	BRONCHOPNEUMONIA	1	0.4	3	0.3	0	0	2	0.4	0	0

(Continued)

MEDDRA VERSION 7.1
 A PATIENT CAN ONLY BE COUNTED ONCE WITHIN ANY SPECIFIC PREFERRED TERM
 ALL PERCENTAGES SHOWN ARE OF TOTAL PATIENTS IN TREATMENT GROUP AND DO NOT NECESSARILY ADD UP TO 100%
 WITHIN SYSTEM ORGAN CLASS
 ADVERSE EVENTS OCCURRING PRE-TRIAL ARE NOT INCLUDED
 ADVERSE EVENTS OCCURRING DURING FOLLOW-UP (I.E. OCCURRING WITHIN 30 DAYS AFTER DISCONTINUATION OF
 INVESTIGATIONAL PRODUCT) ARE INCLUDED

1839IL/0709

NUMBER OF PATIENTS WITH SERIOUS ADVERSE EVENTS

POPULATION: EVALUABLE-FOR- SAFETY

SYSTEM ORGAN CLASS	PREFERRED TERM	TREATMENT RECEIVED									
		GEFITINIB					PLACEBO				
		ORIENTAL		NON-ORIENTAL		%	ORIENTAL		NON-ORIENTAL		%
		N	%	N	%		N	%	N	%	
INFECTIONS AND INFESTATIONS	CELULITIS	0	0	0	0	0	0	0	0	1	0.2
	DIABETIC FOOT INFECTION	1	0.4	0	0	0	0	0	0	0	0
	DIARRHOEA INFECTIOUS	0	0	1	0.1	0	0	0	0	0	0
	DIVERTICULITIS	0	0	1	0.1	0	0	0	0	0	0
	EMPHYEMA	2	0.9	1	0.1	0	0	0	0	0	0
	GASTROENTERITIS	1	0.4	1	0.1	0	0	0	0	0	0
	HERPES ZOSTER	1	0.4	1	0.1	0	0	0	0	0	0
	INFECTION	0	0	1	0.1	1	0.9	1	0.9	0	0
	INFLUENZA	0	0	0	0	0	0	0	0	1	0.2
	LARYNGOTRACHEITIS	0	0	0	0	0	0	0	0	1	0.2
	LOBAR PNEUMONIA	1	0.4	0	0	1	0.9	1	0.9	1	0.2

(Continued)

MEDRA VERSION 7.1
 A PATIENT CAN ONLY BE COUNTED ONCE WITHIN ANY SPECIFIC PREFERRED TERM
 ALL PERCENTAGES SHOWN ARE OF TOTAL PATIENTS IN TREATMENT GROUP AND DO NOT NECESSARILY ADD UP TO 100%
 WITHIN SYSTEM ORGAN CLASS
 ADVERSE EVENTS OCCURRING PRE-TRIAL ARE NOT INCLUDED
 ADVERSE EVENTS OCCURRING DURING FOLLOW-UP (I.E. OCCURRING WITHIN 30 DAYS AFTER DISCONTINUATION OF
 INVESTIGATIONAL PRODUCT) ARE INCLUDED

1839IL/0709

NUMBER OF PATIENTS WITH SERIOUS ADVERSE EVENTS

POPULATION: EVALUABLE-FOR- SAFETY

SYSTEM ORGAN CLASS	PREFERRED TERM	TREATMENT RECEIVED							
		GEFITINIB			PLACEBO				
		ORIENTAL N=235	NON-ORIENTAL N=891	%	ORIENTAL N=107	NON-ORIENTAL N=455	%		
INFECTIONS AND INFESTATIONS	LOWER RESPIRATORY TRACT INFECTION	0	0	0.1	1	0.9	5	1.1	
	LUNG ABSCESS	0	0	0.2	0	0	0	0	
	LUNG INFECTION	0	0	0	0	0	1	0.2	
	ORCHITIS	0	0	0	0	0	1	0.2	
	PNEUMONIA	14	6.0	19	2.1	9	8.4	6	1.3
	PNEUMONIA BACTERIAL	0	0	1	0.1	0	0	0	
	PNEUMONIA KLEBSIELLA	1	0.4	0	0	0	0	0	
	PNEUMONIA MORAXELLA	0	0	0	0	0	0	0	
	PNEUMONIA STREPTOCOCCAL	1	0.4	0	0	0	0	0	
	PULMONARY SEPSIS	0	0	1	0.1	0	0	0	
	PYOTHORAX	0	0	1	0.1	0	0	0	

(Continued)

MEDDRA VERSION 7.1
 A PATIENT CAN ONLY BE COUNTED ONCE WITHIN ANY SPECIFIC PREFERRED TERM
 ALL PERCENTAGES SHOWN ARE OF TOTAL PATIENTS IN TREATMENT GROUP AND DO NOT NECESSARILY ADD UP TO 100%
 WITHIN SYSTEM ORGAN CLASS
 ADVERSE EVENTS OCCURRING PRE-TRIAL ARE NOT INCLUDED
 ADVERSE EVENTS OCCURRING DURING FOLLOW-UP (I.E. OCCURRING WITHIN 30 DAYS AFTER DISCONTINUATION OF
 INVESTIGATIONAL PRODUCT) ARE INCLUDED

1839IL/0709

NUMBER OF PATIENTS WITH SERIOUS ADVERSE EVENTS

POPULATION: EVALUABLE-FOR-SAFETY

SYSTEM ORGAN CLASS	PREFERRED TERM	TREATMENT RECEIVED								
		GEFITINIB				PLACEBO				
		ORIENTAL		NON-ORIENTAL		ORIENTAL		NON-ORIENTAL		
		N=235		N=891		N=107		N=455		
		N	%	N	%	N	%	N	%	
INFECTIONS AND INFESTATIONS	RESPIRATORY TRACT INFECTION	0	0	4	0.4	2	1.9	1	0.2	
	SEPSIS	2	0.9	2	0.2	1	0.9	0	0	
	SEPTIC SHOCK	3	1.3	1	0.1	1	0.9	0	0	
	SPLENIC INFECTION	0	0	0	0	0	0	1	0.2	
	STAPHYLOCOCCAL INFECTION	0	0	1	0.1	0	0	0	0	
	SUBCUTANEOUS ABSCESS	1	0.4	0	0	0	0	0	0	
	URINARY TRACT INFECTION	0	0	1	0.1	0	0	0	0	
	VIRAL INFECTION	1	0.4	0	0	0	0	0	0	
	WOUND INFECTION	1	0.4	0	0	1	0.9	0	0	
	TOTAL	0	0	6	0.7	0	0	2	0.4	
	INJURY, POISONING AND PROCEDURAL COMPLICATIONS	FEMORAL NECK FRACTURE	0	0	1	0.1	0	0	1	0.2
		FEMUR FRACTURE	0	0	2	0.2	0	0	0	0

(Continued)

MEDDRA VERSION 7.1
 A PATIENT CAN ONLY BE COUNTED ONCE WITHIN ANY SPECIFIC PREFERRED TERM
 ALL PERCENTAGES SHOWN ARE OF TOTAL PATIENTS IN TREATMENT GROUP AND DO NOT NECESSARILY ADD UP TO 100%
 WITHIN SYSTEM ORGAN CLASS
 ADVERSE EVENTS OCCURRING PRE-TRIAL ARE NOT INCLUDED
 ADVERSE EVENTS OCCURRING DURING FOLLOW-UP (I.E. OCCURRING WITHIN 30 DAYS AFTER DISCONTINUATION OF
 INVESTIGATIONAL PRODUCT) ARE INCLUDED

1839IL/0709

NUMBER OF PATIENTS WITH SERIOUS ADVERSE EVENTS
POPULATION: EVALUABLE-FOR- SAFETY

SYSTEM ORGAN CLASS	PREFERRED TERM	TREATMENT RECEIVED					
		GEFITINIB			PLACEBO		
		ORIENTAL	NON-ORIENTAL	%	ORIENTAL	NON-ORIENTAL	%
		N=891			N=455		
		N	%	N	%	N	%
INJURY, POISONING AND PROCEDURAL COMPLICATIONS	HIP FRACTURE	0	0	2	0.2	0	0
	HUMERUS FRACTURE	0	0	1	0.1	0	0
	RADIATION FIBROSIS - LUNG	0	0	0	0	0	0
	UPPER LIMB FRACTURE	0	0	1	0.1	0	0
	TOTAL	0	0	2	0.2	0	0
INVESTIGATIONS	BLOOD CREATININE INCREASED	0	0	1	0.1	0	0
	HEPATIC ENZYME INCREASED	0	0	1	0.1	0	0
	PLATELET COUNT DECREASED	0	0	0	0	0	0
	TOTAL	6	2.6	19	2.1	2	1.9
METABOLISM AND NUTRITION DISORDERS	ANOREXIA	0	0	1	0.1	0	0
	CACHEXIA	0	0	0	0	0	0
	DECREASED APPETITE	1	0.4	0	0	0	0
	TOTAL	1	0.4	0	0	0	0

(Continued)

MEDDRA VERSION 7.1
A PATIENT CAN ONLY BE COUNTED ONCE WITHIN ANY SPECIFIC PREFERRED TERM
ALL PERCENTAGES SHOWN ARE OF TOTAL PATIENTS IN TREATMENT GROUP AND DO NOT NECESSARILY ADD UP TO 100%
WITHIN SYSTEM ORGAN CLASS
ADVERSE EVENTS OCCURRING PRE-TRIAL ARE NOT INCLUDED
ADVERSE EVENTS OCCURRING DURING FOLLOW-UP (I.E. OCCURRING WITHIN 30 DAYS AFTER DISCONTINUATION OF INVESTIGATIONAL PRODUCT) ARE INCLUDED

1839IL/0709

NUMBER OF PATIENTS WITH SERIOUS ADVERSE EVENTS

POPULATION: EVALUABLE-FOR-SAFETY

SYSTEM ORGAN CLASS	PREFERRED TERM	TREATMENT RECEIVED								
		GEFITINIB				PLACEBO				
		ORIENTAL	NON-ORIENTAL	ORIENTAL	NON-ORIENTAL	ORIENTAL	NON-ORIENTAL	ORIENTAL	NON-ORIENTAL	
		N=235		N=891		N=107		N=455		
		N	%	N	%	N	%	N	%	
METABOLISM AND NUTRITION DISORDERS	DEHYDRATION	0	0	13	1.5	1	0.9	5	1.1	
	DIABETIC FOOT	1	0.4	0	0	0	0	0	0	
	HYPERCALCAEMIA	1	0.4	0	0	0	0	0	0	
	HYPERGLYCAEMIA	0	0	2	0.2	0	0	1	0.2	
	HYPERKALAEMIA	0	0	0	0	0	0	1	0.2	
	HYPOCALCAEMIA	0	0	1	0.1	0	0	0	0	
	HYPOGLYCAEMIA	1	0.4	1	0.1	1	0.9	0	0	
	HYPONATRAEMIA	1	0.4	1	0.1	0	0	0	0	
	MALNUTRITION	0	0	1	0.1	0	0	0	0	
	METABOLIC ACIDOSIS	1	0.4	0	0	0	0	0	0	
	TOTAL		2	0.9	3	0.3	0	0	3	0.7
	MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS	BACK PAIN	2	0.9	0	0	0	0	0	0

(Continued)

MEDDRA VERSION 7.1
 A PATIENT CAN ONLY BE COUNTED ONCE WITHIN ANY SPECIFIC PREFERRED TERM
 ALL PERCENTAGES SHOWN ARE OF TOTAL PATIENTS IN TREATMENT GROUP AND DO NOT NECESSARILY ADD UP TO 100%
 WITHIN SYSTEM ORGAN CLASS

ADVERSE EVENTS OCCURRING PRE-TRIAL ARE NOT INCLUDED
 ADVERSE EVENTS OCCURRING DURING FOLLOW-UP (I.E. OCCURRING WITHIN 30 DAYS AFTER DISCONTINUATION OF
 INVESTIGATIONAL PRODUCT) ARE INCLUDED